Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment
NCT ID: NCT01932047
Last Updated: 2013-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1523 participants
OBSERVATIONAL
2010-04-30
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Many advanced cancers are still detected Despite remarkable technological advances for the early diagnosis of cancer in the field last 20 years.
In the type of progressive carcinoma is very high malignancy despite a variety of therapeutic target treatment for refractory cancer.
The refractory cancer patients who main focus of this research defined as the adult solid tumor patients who have failed standard therapy according to the criteria
NCCN / ASCO (American Society of imsangam) / KCSG (Study Group for chemotherapy).
The survival rate of refractory cancer patients are estimated to be 30-40% of the total patients with metastatic solid tumors and these refractory cancers are
difficult to deal with or control to conventional treatment so shows almost close to 100% mortality.
Therefore the new development of therapies for conquer of refractory cancer are urgently required.
■ Preclinical translational research Unmet Needs of Bio-new drug development for conquer of refractory cancer
\- The stage of preclinical translational research (Translational Research) connects between the early stages of development and clinical trials in the stage drug development.
The establishment of foundation based on the translational research is very necessary and this must have proven ability to treat refractory cancer.
The most anti-cancer drugs developed by existing preclinical testing method actually does not show a remarkable effect in many cases in the clinical trials,
even if showed a remarkable inhibitory cancer effect in animal testing.
The exact molecular diagnosis to treat targets and paradigm for the development of new drugs at the same time requires for target treatment.
The tailored cell lines by patients and the proven technology by animal models and unmet need for preclinical translational research is increasing
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The specimen obtainer gives the information of speciman to the manager .
The manager contact to the speciman deleverer and The speciman deleverer transported the specimens safely to the laboratory space.
The written informed consent form should obtained from the subject prior to the surgery.
In the case of blood samples, The total 15 \~ 20 ㎖ blood (only once) extracted from the subject and about 10 \~ 15 ㎖ blood is used for the genomic DNA extraction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patients who are scheduled for collection such as the patient tissue, pleural fluid, cerebro spinal fluid, blood samples for the purpose of surgery and diagnostics
3. The patients who diagnosed with cancer as below - GBM, Colon Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer, Brain metastases, Lymphoma, Bone Metastatic Cancer , Gastric Cancer, Pancreatic Cancer, Gall bladder Cancer, Prostate Cancer, Kidney Cancer, Bladder cancer, Osteosarcoma, Soft tissue sarcoma, Head and neck cancer, 기타 Brain tumor
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Do-hyun Nam
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jueun Kim, Coordinator
Role: STUDY_DIRECTOR
Institutional Refractory Cancer Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, Gyunggido, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-04-004
Identifier Type: -
Identifier Source: org_study_id